492 related articles for article (PubMed ID: 23545931)
1. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging.
Fabi SG; Goldman MP
J Drugs Dermatol; 2013 Mar; 12(3):S32-7. PubMed ID: 23545931
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of two commercial hyperpigmentation kits in the treatment of facial hyperpigmentation and photo-aging.
Fabi S; Massaki N; Goldman MP
J Drugs Dermatol; 2012 Aug; 11(8):964-8. PubMed ID: 22859242
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation.
Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Wu DC; Goldman MP
J Drugs Dermatol; 2017 Nov; 16(11):1127-1132. PubMed ID: 29141061
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months.
Bruce S
J Drugs Dermatol; 2013 Mar; 12(3):S27-31. PubMed ID: 23545930
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
Makino ET; Mehta RC; Garruto J; Gotz V; Sigler ML; Herndon JH
J Drugs Dermatol; 2013 Mar; 12(3):s21-6. PubMed ID: 23545929
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
Makino ET; Herndon JH; Sigler ML; Gotz V; Garruto J; Mehta RC
J Drugs Dermatol; 2012 Dec; 11(12):1478-82. PubMed ID: 23377519
[TBL] [Abstract][Full Text] [Related]
7. Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging.
Serra M; Bohnert K; Narda M; Granger C; Sadick N
J Drugs Dermatol; 2018 Dec; 17(12):1310-1315. PubMed ID: 30586263
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation.
Makino ET; Mehta RC; Banga A; Jain P; Sigler ML; Sonti S
J Drugs Dermatol; 2013 Mar; 12(3):s16-20. PubMed ID: 23545928
[TBL] [Abstract][Full Text] [Related]
9. Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study.
Lowe N; Horwitz S; Tanghetti E; Draelos Z; Menter A
J Cosmet Laser Ther; 2006 Sep; 8(3):121-7. PubMed ID: 16971360
[TBL] [Abstract][Full Text] [Related]
10. Hydroquinone-free multimodal topical regimen for facial hyperpigmentation.
Foad MS; Winters E
J Drugs Dermatol; 2013 Mar; 12(3):S42-4. PubMed ID: 23545933
[TBL] [Abstract][Full Text] [Related]
11. Combination of In-Office Chemical Peels With a Topical Comprehensive Pigmentation Control Product in Skin of Color Subjects With Facial Hyperpigmentation.
Downie J; Schneider K; Goberdhan L; Makino ET; Mehta RC
J Drugs Dermatol; 2017 Apr; 16(4):301-306. PubMed ID: 28403262
[TBL] [Abstract][Full Text] [Related]
12. Further enhancement of facial appearance with a hydroquinone skin care system plus tretinoin in patients previously treated with botulinum toxin Type A.
Schlessinger J; Kenkel J; Werschler P
Aesthet Surg J; 2011 Jul; 31(5):529-39. PubMed ID: 21719866
[TBL] [Abstract][Full Text] [Related]
13. Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone.
Dahl A; Yatskayer M; Raab S; Oresajo C
J Drugs Dermatol; 2013 Jan; 12(1):52-8. PubMed ID: 23377328
[TBL] [Abstract][Full Text] [Related]
14. The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types.
Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Fabi SG
Dermatol Surg; 2018 Oct; 44(10):1304-1310. PubMed ID: 29659405
[TBL] [Abstract][Full Text] [Related]
15. Clinical Evaluation of a 4% Hydroquinone + 1% Retinol Treatment Regimen for Improving Melasma and Photodamage in Fitzpatrick Skin Types III-VI.
Rendon MI; Barkovic S
J Drugs Dermatol; 2016 Nov; 15(11):1435-1441. PubMed ID: 28095558
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the benefits of a topical treatment in the improvement of photodamaged hands with age spots, freckles, and/or discolorations.
Gold MH; Gallagher C
J Drugs Dermatol; 2013 Dec; 12(12):1468-72. PubMed ID: 24301250
[TBL] [Abstract][Full Text] [Related]
17. In Vitro and In Vivo Efficacy and Tolerability of a Non-Hydroquinone, Multi-Action Skin Tone Correcting Cream.
Grimes PE; McDaniel DH; Wortzman M; Nelson D
J Drugs Dermatol; 2019 Jul; 18(7):642-648. PubMed ID: 31329402
[TBL] [Abstract][Full Text] [Related]
18. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J; Fabi S; Robinson D; Bajaj S; Geronemus R; Bell M; Widgerow A
J Drugs Dermatol; 2023 Apr; 22(4):333-338. PubMed ID: 37026875
[TBL] [Abstract][Full Text] [Related]
19. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
Kaufman BP; Alexis AF
J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
[TBL] [Abstract][Full Text] [Related]
20. Novel approach to the treatment of hyperpigmented photodamaged skin: 4% hydroquinone/0.3% retinol versus tretinoin 0.05% emollient cream.
Draelos ZD
Dermatol Surg; 2005 Jul; 31(7 Pt 2):799-804. PubMed ID: 16029670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
